MeSH term
Frequency | Condition_Probility | Aged | 8 | 0.0 |
Humans | 103 | 0.0 |
Risk | 2 | 0.0 |
Time Factors | 3 | 0.0 |
Asian Continental Ancestry Group/*genetics | 3 | 0.0 |
China | 3 | 0.0 |
*Evolution, Molecular | 3 | 0.0 |
*Gene Frequency | 2 | 0.0 |
HLA-DP Antigens/*genetics | 46 | 55.0 |
Research Support, Non-U.S. Gov't | 59 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Comparative Study | 20 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Gene Frequency | 29 | 0.0 |
HLA-DP Antigens/*analysis | 4 | 66.0 |
Histocompatibility Testing/*methods | 11 | 7.0 |
*Alleles | 12 | 0.0 |
HLA Antigens/*genetics | 6 | 0.0 |
*Linkage Disequilibrium | 3 | 1.0 |
Animals | 2 | 0.0 |
*Genes, MHC Class II | 9 | 2.0 |
Haplotypes | 11 | 0.0 |
Polymorphism, Genetic | 15 | 0.0 |
Adult | 26 | 0.0 |
Case-Control Studies | 8 | 0.0 |
Female | 36 | 0.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
HLA-DP Antigens/genetics | 7 | 14.0 |
HLA-DQ Antigens/genetics | 7 | 2.0 |
HLA-DR Antigens/genetics | 7 | 1.0 |
Major Histocompatibility Complex/*genetics | 2 | 1.0 |
Male | 33 | 0.0 |
Polymerase Chain Reaction | 22 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
*Histocompatibility | 2 | 3.0 |
Proportional Hazards Models | 2 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Survival Analysis | 2 | 0.0 |
*Tissue Donors | 4 | 2.0 |
Berylliosis/*genetics/immunology | 2 | 100.0 |
Chronic Disease | 6 | 0.0 |
Genotype | 20 | 0.0 |
Middle Aged | 18 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
ATP-Binding Cassette Transporters/*genetics | 2 | 0.0 |
Arthritis, Juvenile Rheumatoid/*genetics | 2 | 11.0 |
Chi-Square Distribution | 3 | 0.0 |
Child | 10 | 0.0 |
Child, Preschool | 7 | 0.0 |
HLA-DR Antigens/*genetics | 7 | 1.0 |
Odds Ratio | 5 | 0.0 |
Adolescent | 14 | 0.0 |
Alleles | 42 | 0.0 |
Base Sequence | 22 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 2 | 0.0 |
English Abstract | 3 | 0.0 |
*Exons | 2 | 0.0 |
HLA-DQ Antigens/*genetics | 7 | 1.0 |
Molecular Sequence Data | 23 | 0.0 |
Histocompatibility Testing | 12 | 1.0 |
Linkage Disequilibrium/*genetics | 2 | 2.0 |
Pedigree | 3 | 0.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 15 | 0.0 |
Receptors, Retinoic Acid/*genetics | 3 | 5.0 |
Retinoid X Receptors | 3 | 1.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Transcription Factors/*genetics | 3 | 0.0 |
Phenotype | 8 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Age of Onset | 3 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Risk Factors | 7 | 0.0 |
Cell Line | 5 | 0.0 |
Polymerase Chain Reaction/*methods | 6 | 1.0 |
Reproducibility of Results | 3 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
Transplantation, Homologous | 3 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
*Genotype | 3 | 1.0 |
Infant, Newborn | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
*Polymorphism, Genetic | 8 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Disease Susceptibility | 3 | 0.0 |
*Bone Marrow Transplantation | 5 | 1.0 |
HLA-DP Antigens/genetics/*immunology | 6 | 54.0 |
Histocompatibility Antigens Class II/*genetics | 4 | 2.0 |
*Histocompatibility Testing | 4 | 1.0 |
Lymphocyte Culture Test, Mixed | 5 | 0.0 |
Tissue Donors | 3 | 1.0 |
Japan/epidemiology | 2 | 0.0 |
Random Allocation | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Heterozygote | 6 | 0.0 |
Histocompatibility Testing/methods | 2 | 4.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Sarcoidosis/*genetics | 2 | 12.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Indians, South American/*genetics | 2 | 3.0 |
Linkage Disequilibrium | 5 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Genes, MHC Class II/*genetics | 4 | 5.0 |
HLA-DP Antigens/*immunology | 4 | 33.0 |
Acute Disease | 4 | 0.0 |
Bone Marrow Transplantation | 3 | 1.0 |
Bone Marrow Transplantation/*immunology | 7 | 5.0 |
HLA-DP Antigens/*genetics/immunology | 2 | 28.0 |
Ethnic Groups | 2 | 0.0 |
Arthritis, Rheumatoid/genetics/*immunology | 2 | 5.0 |
Infant | 4 | 0.0 |
*Lymphocyte Culture Test, Mixed | 3 | 5.0 |
HLA-DP Antigens/*analysis/genetics | 2 | 50.0 |
Arthritis, Rheumatoid/*genetics/*immunology | 2 | 9.0 |
Oligonucleotide Probes | 4 | 0.0 |
Germany | 2 | 0.0 |
Oligonucleotides | 2 | 3.0 |
HLA-DP Antigens/analysis/*genetics | 2 | 66.0 |
European Continental Ancestry Group | 3 | 0.0 |
HLA Antigens/genetics | 2 | 0.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Histocompatibility Antigens Class II/genetics | 2 | 1.0 |
*Polymerase Chain Reaction | 3 | 1.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
DNA/*genetics | 2 | 0.0 |
European Continental Ancestry Group/*genetics | 3 | 0.0 |
Algorithms | 2 | 0.0 |
Exons | 3 | 0.0 |
DNA/genetics | 4 | 0.0 |
*HLA-DP Antigens/genetics | 2 | 66.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
